Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Leukemia Retrieve available abstracts of 341 articles: HTML format

Single Articles

June 2025
1. VIT F, Bittolo T, Zucchetto A, Papotti R, et al
   Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.
   Leukemia. 2025 Jun 18. doi: 10.1038/s41375-025-02650.
   PubMed     Abstract available
   
   
   
2. IKOMA Y, Nakamura N, Kaneda Y, Takamori H, et al
   Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
   Leukemia. 2025;39:1362-1367.
   PubMed     Abstract available
   
   
   
3. BUCKLEY M, Yeung DT, White DL, Eadie LN, et al
   T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.
   Leukemia. 2025;39:1294-1310.
   PubMed     Abstract available
   
   
   
4. VELETIC I, Harris DM, Rozovski U, Bertilaccio MTS, et al
   CLL cell-derived exosomes alter the immune and hematopoietic systems.
   Leukemia. 2025;39:1380-1394.
   PubMed     Abstract available
   
   
   May 2025
5. ZHANG Y, Feng Z, Du J, Liu H, et al
   High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.
   Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02655.
   PubMed     Abstract available
   
   
   
6. BOHRA A, Hassan R, Zanwar S, Jevremovic D, et al
   Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia.
   Leukemia. 2025 May 26. doi: 10.1038/s41375-025-02653.
   PubMed    
   
   
   
7. DEMBITZ V, James SC, Gallipoli P
   Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities.
   Leukemia. 2025 May 22. doi: 10.1038/s41375-025-02645.
   PubMed     Abstract available
   
   
   
8. AUER F, Morcos MNF, Sipola M, Akhtar I, et al
   Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.
   Leukemia. 2025 May 20. doi: 10.1038/s41375-025-02626.
   PubMed     Abstract available
   
   
   
9. KUHN MWM, Pemmaraju N, Heidel FH
   The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.
   Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639.
   PubMed     Abstract available
   
   
   
10. NGUYEN NTK, Yao H, Hosokawa K, Esaki Y, et al
    Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF-beta-activated Alcam(+) bone lining cells, creating a self-sustaining environment.
    Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02640.
    PubMed    
    
    
    
11. WANG'ONDU RW, Ashcraft E, Chang TC, Roberts KG, et al
    Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02633.
    PubMed     Abstract available
    
    
    
12. BATALLER A, Goulart HE, Issa GC, DiNardo CD, et al
    Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements.
    Leukemia. 2025 May 9. doi: 10.1038/s41375-025-02634.
    PubMed     Abstract available
    
    
    
13. IZUMI S, Ohtani K, Matsumoto M, Shibata S, et al
    Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia.
    Leukemia. 2025 May 8. doi: 10.1038/s41375-025-02638.
    PubMed     Abstract available
    
    
    
14. NGUYEN LXT, Zhang B, Hoang DH, Zhao D, et al
    Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
    Leukemia. 2025 May 5. doi: 10.1038/s41375-025-02637.
    PubMed    
    
    
    
15. LAUSEKER M, Hoffmann VS, Pfirrmann M
    Prognostic scoring systems in chronic myeloid leukaemia.
    Leukemia. 2025;39:1046-1052.
    PubMed     Abstract available
    
    
    
16. TAKAMORI H, Huang YJ, Fukushima H, Yokoyama K, et al
    Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation.
    Leukemia. 2025;39:1218-1227.
    PubMed     Abstract available
    
    
    April 2025
17. HASAN MK, Widhopf Ii GF, Ghia EM, Kipps TJ, et al
    Wnt5a induces ROR1 dependent NF-kappaB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02616.
    PubMed     Abstract available
    
    
    
18. MECKLENBRAUCK R, Borchert N, Gabdoulline R, Poll P, et al
    Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02622.
    PubMed    
    
    
    
19. KRIZKOVA J, Polivkova V, Laznicka A, Curik N, et al
    Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02609.
    PubMed     Abstract available
    
    
    
20. GHANI F, Zubair AC
    Possible impacts of cosmic radiation on leukemia development during human deep space exploration.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02624.
    PubMed     Abstract available
    
    
    
21. THORVALDSDOTTIR B, Mansouri L, Sutton LA, Nadeu F, et al
    ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02615.
    PubMed     Abstract available
    
    
    
22. ZHOU T, Short NJ, Jain N, Patel KP, et al
    Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02588.
    PubMed    
    
    
    
23. WU JF, Feliciano EJG, Singh A, Tremblay D, et al
    National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients.
    Leukemia. 2025 Apr 23. doi: 10.1038/s41375-025-02598.
    PubMed    
    
    
    
24. SHIMA Y, Yamagata K, Kuroki Y, Sasaki K, et al
    Loss of NOL10 leads to impaired disease progression of NUP98::DDX10 leukemia.
    Leukemia. 2025 Apr 22. doi: 10.1038/s41375-025-02607.
    PubMed     Abstract available
    
    
    
25. ASHAYE A, Shi L, Aldoss I, Montesinos P, et al
    Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.
    Leukemia. 2025 Apr 16. doi: 10.1038/s41375-025-02608.
    PubMed     Abstract available
    
    
    
26. XU Y, Mou J, Wang Y, Zhou W, et al
    Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02618.
    PubMed    
    
    
    
27. NIEDERMAYER A, Stursberg J, Bergmann AK, Zimmermann M, et al
    Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02591.
    PubMed    
    
    
    
28. DECHOW A, Timonen S, Ianevski A, Jiang Q, et al
    Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02577.
    PubMed     Abstract available
    
    
    
29. HSU CJ, Schraw JM, Desrosiers TA, Janitz AE, et al
    All genetic subtypes of B-cell acute lymphoblastic leukemia exhibit increased incidence rates in children with Down syndrome.
    Leukemia. 2025 Apr 11. doi: 10.1038/s41375-025-02602.
    PubMed    
    
    
    
30. XING C, Zhang H, Zheng M, Lu Q, et al
    Fabp4 is essential for the maintenance of leukemia stem cells while sparing hematopoietic stem cells.
    Leukemia. 2025 Apr 10. doi: 10.1038/s41375-025-02568.
    PubMed    
    
    
    
31. CORTES JE, Lang F, Rea D, Hochhaus A, et al
    Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02592.
    PubMed     Abstract available
    
    
    
32. KAYA F, Bewicke-Copley F, Miettinen JJ, Casado P, et al
    DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02593.
    PubMed     Abstract available
    
    
    
33. HOCHHAUS A, Kim DW, Cortes JE, Sasaki K, et al
    Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1(T315I) treated with at least 2 prior TKIs: Phase 1 final results.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02578.
    PubMed     Abstract available
    
    
    
34. PAGANO L, Maschmeyer G, Lamoth F, Blennow O, et al
    Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL).
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02586.
    PubMed     Abstract available
    
    
    
35. REINHARDT C, Ochsenbein AF
    Immune checkpoints regulate acute myeloid leukemia stem cells.
    Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02566.
    PubMed     Abstract available
    
    
    
36. LI R, Wu X, Xue K, Wu S, et al
    CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia.
    Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02589.
    PubMed     Abstract available
    
    
    
37. BUSSOT L, Poulain S, Nudel Ortmans M, Davi F, et al
    Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.
    Leukemia. 2025 Apr 1. doi: 10.1038/s41375-025-02555.
    PubMed    
    
    
    
38. HUANG J, Xie J, Wang Y, Sheng M, et al
    STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem/progenitor cells.
    Leukemia. 2025;39:929-941.
    PubMed     Abstract available
    
    
    
39. SHI C, Tian Z, Yan J, Zhang M, et al
    Immunotherapy targeting a leader sequence cathepsin G-derived peptide.
    Leukemia. 2025;39:888-898.
    PubMed     Abstract available
    
    
    March 2025
40. AYYADEVARA VSSA, Wertheim G, Gaur S, Chukinas JA, et al
    DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.
    Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02575.
    PubMed     Abstract available
    
    
    
41. CHARLES CANO F, Kloos A, Hebalkar RY, Plenge T, et al
    XPO1-dependency of DEK::NUP214 leukemia.
    Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02570.
    PubMed     Abstract available
    
    
    
42. JERKEMAN M, Mellgren K, Sonnevi K, Lisak M, et al
    Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.
    Leukemia. 2025 Mar 26. doi: 10.1038/s41375-025-02573.
    PubMed    
    
    
    
43. STOLTZE U, Junk SV, Byrjalsen A, Cave H, et al
    Overt and covert genetic causes of pediatric acute lymphoblastic leukemia.
    Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02535.
    PubMed     Abstract available
    
    
    
44. GEYER J, Opoku KB, Lin J, Ramkissoon L, et al
    Real-time genomic characterization of pediatric acute leukemia using adaptive sampling.
    Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02565.
    PubMed     Abstract available
    
    
    
45. COLE FM, Laszlo GS, Lunn-Halbert MC, Kehret AR, et al
    Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).
    Leukemia. 2025 Mar 21. doi: 10.1038/s41375-025-02571.
    PubMed    
    
    
    
46. ROMPIETTI C, Adamo FM, Sorcini D, De Falco F, et al
    Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice.
    Leukemia. 2025 Mar 20. doi: 10.1038/s41375-025-02557.
    PubMed     Abstract available
    
    
    
47. SHAH BD, Cassaday RD, Park JH, Houot R, et al
    Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
    Leukemia. 2025 Mar 19. doi: 10.1038/s41375-025-02532.
    PubMed     Abstract available
    
    
    
48. SPERB N, Maksakova IA, Escano L, Abraham L, et al
    The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation.
    Leukemia. 2025 Mar 17. doi: 10.1038/s41375-025-02558.
    PubMed     Abstract available
    
    
    
49. WANG H, Suo S, Li D, Li J, et al
    Comparison of subcutaneous injection versus intravenous infusion of cytarabine for induction therapy in adult acute myeloid leukemia.
    Leukemia. 2025 Mar 12. doi: 10.1038/s41375-025-02556.
    PubMed    
    
    
    
50. KLEPZIG H, Herling M, Pflug N, Braun T, et al
    Models for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity.
    Leukemia. 2025 Mar 7. doi: 10.1038/s41375-025-02553.
    PubMed     Abstract available
    
    
    
51. MILLOT F, Ampatzidou M, Moulik NR, Tewari S, et al
    Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations.
    Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02543.
    PubMed     Abstract available
    
    
    
52. LIPTON JH, Rea D
    Living, not just surviving, with chronic myeloid leukemia - quality of life to the front of the line.
    Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02548.
    PubMed    
    
    
    
53. BRUNMEIR R, Ying L, Yan J, Hee YT, et al
    EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML.
    Leukemia. 2025;39:650-662.
    PubMed     Abstract available
    
    
    February 2025
54. REUVEKAMP T, Ngai LL, den Hartog D, Carbaat-Ham J, et al
    CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.
    Leukemia. 2025 Feb 27. doi: 10.1038/s41375-025-02539.
    PubMed    
    
    
    
55. DINARDO CD, Jen WY, Takahashi K, Kadia TM, et al
    Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
    Leukemia. 2025 Feb 25. doi: 10.1038/s41375-025-02531.
    PubMed     Abstract available
    
    
    
56. GIUDICE V, Selleri C
    How fast does leukemia progress?
    Leukemia. 2025 Feb 24. doi: 10.1038/s41375-025-02536.
    PubMed    
    
    
    
57. MINAMI M, Sakoda T, Kawano G, Kochi Y, et al
    Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of PML::RARalpha.
    Leukemia. 2025 Feb 20. doi: 10.1038/s41375-025-02530.
    PubMed     Abstract available
    
    
    
58. HORMANN FM, Rudd SG
    Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.
    Leukemia. 2025 Feb 17. doi: 10.1038/s41375-025-02529.
    PubMed     Abstract available
    
    
    
59. ABEDIN SM, Guru Murthy GS, Hamadani M, Michaelis LC, et al
    Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
    Leukemia. 2025 Feb 15. doi: 10.1038/s41375-025-02528.
    PubMed     Abstract available
    
    
    
60. OKABE S, Arai Y, Gotoh A
    Correspondence to: "Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.
    Leukemia. 2025 Feb 6. doi: 10.1038/s41375-025-02521.
    PubMed    
    
    
    
61. SU Y, Han Z, Ji Y, Liu A, et al
    Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database.
    Leukemia. 2025 Feb 2. doi: 10.1038/s41375-025-02514.
    PubMed     Abstract available
    
    
    
62. FALINI B, Sorcini D, Perriello VM, Sportoletti P, et al
    Functions of the native NPM1 protein and its leukemic mutant.
    Leukemia. 2025;39:276-290.
    PubMed     Abstract available
    
    
    
63. YANG S, Zhang X, Gale RP, Huang X, et al
    Is there really an accelerated phase of chronic myeloid leukaemia at presentation?
    Leukemia. 2025;39:391-399.
    PubMed     Abstract available
    
    
    
64. CALVO J, Naguibneva I, Kypraios A, Gilain F, et al
    High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
    Leukemia. 2025;39:323-336.
    PubMed     Abstract available
    
    
    
65. ORTI G, Peczynski C, Boreland W, O'Reilly M, et al
    Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
    Leukemia. 2025;39:431-437.
    PubMed     Abstract available
    
    
    January 2025
66. ABLE M, Kasper MA, Vick B, Schwach J, et al
    Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates.
    Leukemia. 2025 Jan 27. doi: 10.1038/s41375-024-02510.
    PubMed     Abstract available
    
    
    
67. LIU J, Kharazmi E, Liang Q, Chen Y, et al
    Maternal weight during pregnancy and risk of childhood acute lymphoblastic leukemia in offspring.
    Leukemia. 2025 Jan 26. doi: 10.1038/s41375-025-02517.
    PubMed     Abstract available
    
    
    
68. TREMBLAY CS, Saw J, Yan F, Boyle JA, et al
    Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2025 Jan 23. doi: 10.1038/s41375-024-02491.
    PubMed     Abstract available
    
    
    
69. LAUWEREINS L, Van Thillo Q, Demeyer S, Mentens N, et al
    TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia.
    Leukemia. 2025 Jan 21. doi: 10.1038/s41375-025-02513.
    PubMed     Abstract available
    
    
    
70. ADDINSELL HM, Cant R, Hull NJ, Wang YH, et al
    Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization.
    Leukemia. 2025 Jan 15. doi: 10.1038/s41375-024-02511.
    PubMed    
    
    
    
71. ANABTAWI N, Nicolet D, Alotaibi N, Buelow DR, et al
    Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.
    Leukemia. 2025 Jan 13. doi: 10.1038/s41375-024-02498.
    PubMed     Abstract available
    
    
    
72. SHAHSWAR R, Gabdoulline R, Krueger K, Wichmann M, et al
    A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
    Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501.
    PubMed     Abstract available
    
    
    
73. SHIMOSATO Y, Yamamoto K, Jia Y, Zhang W, et al
    NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation.
    Leukemia. 2025;39:75-86.
    PubMed     Abstract available
    
    
    
74. STRULLU M, Caye-Eude A, Robert E, Renard JM, et al
    CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL.
    Leukemia. 2025;39:64-74.
    PubMed     Abstract available
    
    
    
75. JACOBY MA, Duncavage ED, Khanna A, Chang GS, et al
    Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
    Leukemia. 2025;39:166-177.
    PubMed     Abstract available
    
    
    
76. LI Z, Fierstein S, Tanaka-Yano M, Frenis K, et al
    The epigenetic state of the cell of origin defines mechanisms of leukemogenesis.
    Leukemia. 2025;39:87-97.
    PubMed     Abstract available
    
    
    December 2024
77. SHI Z, Li J, Ding J, Zhang Y, et al
    ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis.
    Leukemia. 2024 Dec 19. doi: 10.1038/s41375-024-02500.
    PubMed     Abstract available
    
    
    
78. NABKI J, Al Deeban B, Sium AM, Cosentino C, et al
    Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.
    Leukemia. 2024 Dec 17. doi: 10.1038/s41375-024-02499.
    PubMed     Abstract available
    
    
    
79. BALESTRA T, Niswander LM, Bagashev A, Loftus JP, et al
    Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
    Leukemia. 2024 Dec 16. doi: 10.1038/s41375-024-02493.
    PubMed     Abstract available
    
    
    
80. ORVAIN C, Milano F, Rodriguez-Arboli E, Othus M, et al
    Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02497.
    PubMed     Abstract available
    
    
    
81. GERRITSEN M, In 't Hout FEM, Knops R, Mandos BLR, et al
    Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02470.
    PubMed    
    
    
    
82. SHIMA H, Tono C, Tanizawa A, Ito M, et al
    Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02488.
    PubMed    
    
    
    
83. ARGYRIADI EA, Steffen IG, Chen-Santel C, Lissat A, et al
    Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study.
    Leukemia. 2024 Dec 11. doi: 10.1038/s41375-024-02474.
    PubMed     Abstract available
    
    
    
84. MITSUYUKI S, Shimomura Y, Mizumaki H, Yanada M, et al
    Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02495.
    PubMed    
    
    
    
85. HAMPEL PJ, Rabe KG, Wang Y, Hwang SR, et al
    Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492.
    PubMed    
    
    
    
86. ARZA-APALATEGI S, Heuts BMH, Bergevoet SM, Meering R, et al
    HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia.
    Leukemia. 2024 Dec 4. doi: 10.1038/s41375-024-02485.
    PubMed     Abstract available
    
    
    
87. SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
    Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.
    Leukemia. 2024 Dec 3. doi: 10.1038/s41375-024-02487.
    PubMed    
    
    
    
88. WALTER W, Nadarajah N, Hutter S, Muller H, et al
    Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.
    Leukemia. 2024;38:2644-2652.
    PubMed     Abstract available
    
    
    
89. HALILOVIC M, Abdelsalam M, Zabkiewicz J, Lazenby M, et al
    Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.
    Leukemia. 2024;38:2561-2572.
    PubMed     Abstract available
    
    
    November 2024
90. LOU J, Zhang Y, Tao J, Jin W, et al
    Infection-related pathway activation and vulnerability to arsenic trioxide in acute promyelocytic leukemia with TTMV::RARA.
    Leukemia. 2024 Nov 28. doi: 10.1038/s41375-024-02481.
    PubMed    
    
    
    
91. HEGDE M, Ahmad MH, Mulet Lazaro R, Sugita M, et al
    The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling.
    Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02471.
    PubMed     Abstract available
    
    
    
92. KAWASHIMA N, Gurnari C, Bravo-Perez C, Kubota Y, et al
    Clonal hematopoiesis in large granular lymphocytic leukemia.
    Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02460.
    PubMed     Abstract available
    
    
    
93. DALTVEIT DS, Morgan E, Colombet M, Steliarova-Foucher E, et al
    Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022.
    Leukemia. 2024 Nov 20. doi: 10.1038/s41375-024-02452.
    PubMed     Abstract available
    
    
    
94. KRISHNAMOORTHY V, Daly J, Kim J, Piatnitca L, et al
    The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9.
    Leukemia. 2024 Nov 17. doi: 10.1038/s41375-024-02454.
    PubMed     Abstract available
    
    
    
95. SHAO Q, Wykretowicz J, Hu N, Bedi K, et al
    Correction: Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
    Leukemia. 2024 Nov 13. doi: 10.1038/s41375-024-02472.
    PubMed    
    
    
    
96. TREMBLAY D, Csizmar C, DiNardo CD, Ball S, et al
    Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.
    Leukemia. 2024 Nov 12. doi: 10.1038/s41375-024-02466.
    PubMed    
    
    
    
97. BOUEYA IL, Sandhow L, Albuquerque JRP, Znaidi R, et al
    Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia.
    Leukemia. 2024 Nov 11. doi: 10.1038/s41375-024-02453.
    PubMed     Abstract available
    
    
    
98. LI X, Zheng M, Ma S, Nie F, et al
    YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.
    Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02451.
    PubMed     Abstract available
    
    
    
99. EL CHAER F, Perissinotti AJ, Loghavi S, Zeidan AM, et al
    Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
    Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02458.
    PubMed     Abstract available
    
    
    
100. SHAO X, Yokomori R, Ong JZL, Shen H, et al
     Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.
     Leukemia. 2024 Nov 2. doi: 10.1038/s41375-024-02455.
     PubMed     Abstract available
     
     
     
101. INNES AJ, Hayden C, Orovboni V, Claudiani S, et al
     Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
     Leukemia. 2024;38:2443-2455.
     PubMed     Abstract available
     
     
     October 2024
102. SHIMONI A, Peczynski C, Labopin M, Kulagin A, et al
     Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.
     Leukemia. 2024 Oct 31. doi: 10.1038/s41375-024-02445.
     PubMed     Abstract available
     
     
     
103. SAFA-TAHAR-HENNI S, Paez Martinez K, Gress V, Esparza N, et al
     Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.
     Leukemia. 2024 Oct 29. doi: 10.1038/s41375-024-02400.
     PubMed     Abstract available
     
     
     
104. SHAO Q, Wykretowicz J, Hu N, Bedi K, et al
     Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
     Leukemia. 2024 Oct 25. doi: 10.1038/s41375-024-02448.
     PubMed     Abstract available
     
     
     
105. NARDI F, Del Prete R, Drago R, Di Rita A, et al
     Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia.
     Leukemia. 2024 Oct 23. doi: 10.1038/s41375-024-02442.
     PubMed     Abstract available
     
     
     
106. YU M, Nah GSS, Krishnan V, Sulaimi FNB, et al
     The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies.
     Leukemia. 2024 Oct 22. doi: 10.1038/s41375-024-02418.
     PubMed     Abstract available
     
     
     
107. YANG C, Hu Y, Gao L, Li Z, et al
     Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.
     Leukemia. 2024 Oct 15. doi: 10.1038/s41375-024-02437.
     PubMed     Abstract available
     
     
     
108. TETTERO JM, Cloos J, Bullinger L
     Acute myeloid leukemia: does sex matter?
     Leukemia. 2024 Oct 14. doi: 10.1038/s41375-024-02435.
     PubMed    
     
     
     
109. YAMAMOTO Y, Iba S, Inaguma Y, Okamoto A, et al
     ELC52: a novel megakaryocytic leukemia cell line with a CALR type 1 mutation.
     Leukemia. 2024 Oct 8. doi: 10.1038/s41375-024-02434.
     PubMed    
     
     
     
110. SUNAMI Y, Yoshino S, Yamazaki Y, Iwamoto T, et al
     Rapid increase of C/EBPalpha p42 induces growth arrest of acute myeloid leukemia (AML) cells by Cop1 deletion in Trib1-expressing AML.
     Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02430.
     PubMed     Abstract available
     
     
     
111. ZHANG N, Wen D, Wang T, Deng J, et al
     Disparities in incidence and mortality of pediatric acute lymphoblastic leukemia across countries with different incomes.
     Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02433.
     PubMed    
     
     
     
112. GODA C, Kulkarni R, Bustos Y, Li W, et al
     Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia.
     Leukemia. 2024 Oct 2. doi: 10.1038/s41375-024-02415.
     PubMed     Abstract available
     
     
     
113. KAZERANI M, Marcinek A, Philipp N, Brauchle B, et al
     Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.
     Leukemia. 2024;38:2270-2275.
     PubMed    
     
     
     
114. LEE YJ, Lee SY, Kim S, Kim SH, et al
     REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity.
     Leukemia. 2024;38:2150-2161.
     PubMed     Abstract available
     
     
     
115. GALE RP, Jiang Q, Apperley JF, Hochhaus A, et al
     Is there really an accelerated phase of chronic myeloid leukaemia?
     Leukemia. 2024;38:2085-2086.
     PubMed    
     
     
     September 2024
116. PATEL SA
     Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.
     Leukemia. 2024 Sep 30. doi: 10.1038/s41375-024-02417.
     PubMed     Abstract available
     
     
     
117. SAKAMOTO KM
     Can PROTACs cure Leukemia?
     Leukemia. 2024 Sep 26. doi: 10.1038/s41375-024-02427.
     PubMed    
     
     
     
118. RAVANDI F, Senapati J, Jain N, Short NJ, et al
     Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma.
     Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02414.
     PubMed     Abstract available
     
     
     
119. HUELSE JM, Bhasin SS, Jacobsen KM, Yim J, et al
     MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunity.
     Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02408.
     PubMed     Abstract available
     
     
     
120. VOLTA L, Myburgh R, Pellegrino C, Koch C, et al
     Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.
     Leukemia. 2024 Sep 18. doi: 10.1038/s41375-024-02409.
     PubMed     Abstract available
     
     
     
121. CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
     Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
     Leukemia. 2024 Sep 17. doi: 10.1038/s41375-024-02412.
     PubMed    
     
     
     
122. ZHANG W, Yamamoto K, Chang YH, Yabushita T, et al
     HDAC7 is a potential therapeutic target in acute erythroid leukemia.
     Leukemia. 2024 Sep 15. doi: 10.1038/s41375-024-02394.
     PubMed     Abstract available
     
     
     
123. LIU B, Zhang X, Zhou Y, Liu H, et al
     USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem cell regeneration and leukemia progression.
     Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02338.
     PubMed     Abstract available
     
     
     
124. RABIAN F, Chevret S, Gruson B, Thepot S, et al
     Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myelodysplasies (GFM) study.
     Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02402.
     PubMed    
     
     
     
125. KORBECKI J, Bosiacki M, Kupnicka P, Barczak K, et al
     CXCR4 as a therapeutic target in acute myeloid leukemia.
     Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02326.
     PubMed     Abstract available
     
     
     
126. HAGERSTRAND D, Oder B, Cortese D, Qu Y, et al
     The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia.
     Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02379.
     PubMed     Abstract available
     
     
     
127. RHEINGOLD SR, Bhojwani D, Ji L, Xu X, et al
     Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.
     Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02395.
     PubMed     Abstract available
     
     
     
128. STUTTERHEIM J, van der Waarden R, de Groot-Kruseman HA, Sonneveld E, et al
     Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
     Leukemia. 2024 Sep 10. doi: 10.1038/s41375-024-02386.
     PubMed     Abstract available
     
     
     
129. LIU T, Xu K, Pardeshi A, Myint SS, et al
     Early-life tobacco exposure is causally implicated in aberrant RAG-mediated recombination in childhood acute lymphoblastic leukemia.
     Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02407.
     PubMed    
     
     
     
130. BOUCHER A, Murray J, Rao S
     Cohesin mutations in acute myeloid leukemia.
     Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02406.
     PubMed     Abstract available
     
     
     
131. WANG J, Jiang B, Li J, Liu L, et al
     Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
     Leukemia. 2024 Sep 5. doi: 10.1038/s41375-024-02382.
     PubMed     Abstract available
     
     
     
132. VAN DER HAM CG, Suurenbroek LC, Kleisman MM, Antic Z, et al
     Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia.
     Leukemia. 2024 Sep 4. doi: 10.1038/s41375-024-02403.
     PubMed     Abstract available
     
     
     
133. JABBOUR E, Apperley J, Cortes J, Rea D, et al
     Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
     Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02385.
     PubMed    
     
     
     
134. TOMA MM, Skorski T
     Star wars against leukemia: attacking the clones.
     Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02369.
     PubMed     Abstract available
     
     
     
135. CRUZ-RODRIGUEZ N, Tang H, Bateman B, Tang W, et al
     BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph(+) leukemias?
     Leukemia. 2024;38:1885-1893.
     PubMed     Abstract available
     
     
     
136. LEYTE-VIDAL A, DeFilippis R, Outhwaite IR, Kwan I, et al
     Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
     Leukemia. 2024;38:2046-2050.
     PubMed    
     
     
     
137. PIEMONTESE S, Labopin M, Choi G, Broers AEC, et al
     Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
     Leukemia. 2024;38:2016-2022.
     PubMed     Abstract available
     
     
     
138. JANN JC, Hergott CB, Winkler M, Liu Y, et al
     Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
     Leukemia. 2024;38:1992-2002.
     PubMed     Abstract available
     
     
     
139. WANG J, Zhang Y, Li L, Wang L, et al
     Nudt15-mediated inflammatory signaling contributes to divergent outcomes in leukemogenesis and hematopoiesis.
     Leukemia. 2024;38:1958-1970.
     PubMed     Abstract available
     
     
     
140. KEWAN T, Bahaj WS, Gurnari C, Ogbue OD, et al
     Clinical and molecular characteristics of extramedullary acute myeloid leukemias.
     Leukemia. 2024;38:2032-2036.
     PubMed    
     
     
     
141. AL AMRI R, Baloda V, Monaghan SA, Rosado FG, et al
     Validation of independent prognostic significance of blast count in a large cohort of MDS patients.
     Leukemia. 2024;38:2064-2067.
     PubMed    
     
     
     
142. SPERK A, Gabriel A, Koch D, Augsburger A, et al
     FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells.
     Leukemia. 2024;38:2027-2031.
     PubMed    
     
     
     
143. JALNAPURKAR SS, Pawar AS, George SS, Antony C, et al
     PHF6 suppresses self-renewal of leukemic stem cells in AML.
     Leukemia. 2024;38:1938-1948.
     PubMed     Abstract available
     
     
     
144. MOORMAN AV, Enshaei A, Murdy D, Joy M, et al
     Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction.
     Leukemia. 2024;38:2023-2026.
     PubMed    
     
     
     
145. HERNANDEZ-SANCHEZ A, Gonzalez T, Sobas M, Strang E, et al
     Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
     Leukemia. 2024;38:1929-1937.
     PubMed     Abstract available
     
     
     
146. LESKE IB, Hantschel O
     The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
     Leukemia. 2024;38:2041-2045.
     PubMed    
     
     
     August 2024
147. DERIGS P, Schubert ML, Dreger P, Schmitt A, et al
     Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
     Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02392.
     PubMed     Abstract available
     
     
     
148. PASTORCZAK A, Urbanska Z, Styka B, Miarka-Walczyk K, et al
     Genetic hallmarks and clinical implications of chromothripsis in childhood T-cell acute lymphoblastic leukemia.
     Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02370.
     PubMed     Abstract available
     
     
     
149. DEMBITZ V, Lawson H, Burt R, Natani S, et al
     Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.
     Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02390.
     PubMed     Abstract available
     
     
     
150. KOEDIJK JB, van der Werf I, Penter L, Vermeulen MA, et al
     A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia.
     Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02381.
     PubMed     Abstract available
     
     
     
151. CUGLIEVAN B, Kantarjian H, Rubnitz JE, Cooper TM, et al
     Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.
     Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02368.
     PubMed     Abstract available
     
     
     
152. SUN Y, Wu Y, Pang G, Huang J, et al
     STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells.
     Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02383.
     PubMed     Abstract available
     
     
     
153. RODRIGUEZ-ARBOLI E, Othus M, Freeman SD, Buccisano F, et al
     Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
     Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02378.
     PubMed    
     
     
     
154. BOUTZEN H, Murison A, Oriecuia A, Bansal S, et al
     Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties.
     Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02358.
     PubMed     Abstract available
     
     
     
155. GAMBACORTI-PASSERINI C, Brummendorf TH, Abruzzese E, Kelly KR, et al
     Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
     Leukemia. 2024 Aug 20. doi: 10.1038/s41375-024-02372.
     PubMed     Abstract available
     
     
     
156. TISSINO E, Gaglio A, Nicolo A, Pozzo F, et al
     The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
     Leukemia. 2024 Aug 14. doi: 10.1038/s41375-024-02376.
     PubMed     Abstract available
     
     
     
157. ATAR D, Ruoff L, Mast AS, Krost S, et al
     Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.
     Leukemia. 2024 Aug 3. doi: 10.1038/s41375-024-02351.
     PubMed     Abstract available
     
     
     
158. CHATAIN N, Baumeister J, Szymanski de Toledo MA, Wong DWL, et al
     Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells.
     Leukemia. 2024;38:1825-1830.
     PubMed     Abstract available
     
     
     
159. HOFERKOVA E, Seda V, Kadakova S, Verner J, et al
     Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs.
     Leukemia. 2024;38:1699-1711.
     PubMed     Abstract available
     
     
     
160. BOUSQUETS-MUNOZ P, Molina O, Varela I, Alvarez-Eguiluz A, et al
     Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML.
     Leukemia. 2024;38:1808-1812.
     PubMed    
     
     
     
161. FONTANA D, Malighetti F, Villa M, Zambon A, et al
     Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.
     Leukemia. 2024;38:1843-1847.
     PubMed    
     
     
     
162. FARHAT M, Croft W, Parry HM, Verma K, et al
     PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL.
     Leukemia. 2024;38:1813-1817.
     PubMed    
     
     
     
163. GALE RP, Phillips GL, Lazarus HM
     A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy.
     Leukemia. 2024;38:1663-1666.
     PubMed    
     
     
     July 2024
164. WONG RL, Choi MY, Wang HY, Kipps TJ, et al
     Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
     Leukemia. 2024 Jul 24. doi: 10.1038/s41375-024-02317.
     PubMed     Abstract available
     
     
     
165. KONOPLEVA M, Milella M, Ruvolo P, Watts JC, et al
     Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
     Leukemia. 2024 Jul 18. doi: 10.1038/s41375-024-02339.
     PubMed    
     
     
     
166. ORVAIN C, Bertoli S, Peterlin P, Desbrosses Y, et al
     Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
     Leukemia. 2024 Jul 17. doi: 10.1038/s41375-024-02335.
     PubMed     Abstract available
     
     
     
167. TERASAKI T, Semba Y, Sasaki K, Imanaga H, et al
     The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells.
     Leukemia. 2024 Jul 11. doi: 10.1038/s41375-024-02343.
     PubMed     Abstract available
     
     
     
168. EFFICACE F, Mahon FX, Richter J, Piciocchi A, et al
     Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
     Leukemia. 2024 Jul 10. doi: 10.1038/s41375-024-02341.
     PubMed     Abstract available
     
     
     
169. OGBUE O, Kewan T, Bravo-Perez C, Unlu S, et al
     Hemolytic versus malproductive anemia in large granular lymphocytic leukemia.
     Leukemia. 2024 Jul 9. doi: 10.1038/s41375-024-02323.
     PubMed    
     
     
     
170. KIM H, Tan TK, Lee DZY, Huang XZ, et al
     Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia.
     Leukemia. 2024 Jul 5. doi: 10.1038/s41375-024-02331.
     PubMed     Abstract available
     
     
     
171. ERNST P, Rinke J, Franke GN, Dicker F, et al
     Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.
     Leukemia. 2024 Jul 4. doi: 10.1038/s41375-024-02327.
     PubMed    
     
     
     
172. DIEDRICH JD, Dong Q, Ferguson DC, Bergeron BP, et al
     Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.
     Leukemia. 2024 Jul 3. doi: 10.1038/s41375-024-02291.
     PubMed    
     
     
     
173. YAMAMOTO Y, Watanabe T, Ureshino H, Kurahashi Y, et al
     DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.
     Leukemia. 2024;38:1613-1616.
     PubMed    
     
     
     
174. SHAO Y, Kay NE, Gale RP, Liang Y, et al
     Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.
     Leukemia. 2024;38:1469-1473.
     PubMed    
     
     
     
175. SCOTT S, Devonshire A, Dillon R, Thiede C, et al
     Recommendations from the AML molecular MRD expert advisory board.
     Leukemia. 2024;38:1638-1641.
     PubMed    
     
     
     
176. MASLAH N, Rety S, Bonnamy M, Aguinaga L, et al
     Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
     Leukemia. 2024;38:1630-1633.
     PubMed    
     
     
     
177. GROSS G, Alkadieri S, Meir A, Itzhaki O, et al
     Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose.
     Leukemia. 2024;38:1534-1540.
     PubMed     Abstract available
     
     
     
178. SHIMONY S, Garcia JS, Keating J, Chen EC, et al
     Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
     Leukemia. 2024;38:1494-1500.
     PubMed     Abstract available
     
     
     
179. KOVECSES O, Mercier FE, McKeague M
     Nucleic acid therapeutics as differentiation agents for myeloid leukemias.
     Leukemia. 2024;38:1441-1454.
     PubMed     Abstract available
     
     
     June 2024
180. YUN H, Zoller J, Zhou F, Rohde C, et al
     The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance.
     Leukemia. 2024 Jun 28. doi: 10.1038/s41375-024-02322.
     PubMed     Abstract available
     
     
     
181. GALE RP, Hochhaus A
     Correction: To Mars and beyond. Space exploration and space medicine in Leukemia.
     Leukemia. 2024 Jun 25. doi: 10.1038/s41375-024-02324.
     PubMed    
     
     
     
182. POZZO F, Forestieri G, Vit F, Ianna G, et al
     Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
     Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02301.
     PubMed     Abstract available
     
     
     
183. YANAGIYA R, Miyatake Y, Watanabe N, Shimizu T, et al
     Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia.
     Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02296.
     PubMed     Abstract available
     
     
     
184. PHILIPPE C, Jaud M, Feral K, Gay A, et al
     Pivotal role of the endoplasmic reticulum stress-related XBP1s/miR-22/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy.
     Leukemia. 2024 Jun 22. doi: 10.1038/s41375-024-02321.
     PubMed     Abstract available
     
     
     
185. ABOU DALLE I, Moukalled N, El Cheikh J, Mohty M, et al
     Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions.
     Leukemia. 2024 Jun 20. doi: 10.1038/s41375-024-02319.
     PubMed     Abstract available
     
     
     
186. MCCARTHY N, Gui G, Dumezy F, Roumier C, et al
     Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.
     Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02300.
     PubMed     Abstract available
     
     
     
187. MIAO H, Chen D, Ropa J, Purohit T, et al
     Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.
     Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02312.
     PubMed     Abstract available
     
     
     
188. SALA-TORRA O, Beppu L, Wu Q, Welch E, et al
     Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients.
     Leukemia. 2024 Jun 15. doi: 10.1038/s41375-024-02285.
     PubMed    
     
     
     
189. GREVER M, Andritsos L, Anghelina M, Arons E, et al
     Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
     Leukemia. 2024 Jun 8. doi: 10.1038/s41375-024-02280.
     PubMed    
     
     
     
190. OSTERGAARD A, Fiocco M, de Groot-Kruseman H, Moorman AV, et al
     ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
     Leukemia. 2024 Jun 6. doi: 10.1038/s41375-024-02287.
     PubMed     Abstract available
     
     
     
191. ZHANG MY, Othus M, McMillen K, Erba HP, et al
     Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
     Leukemia. 2024 Jun 3. doi: 10.1038/s41375-024-02288.
     PubMed     Abstract available
     
     
     
192. VAN DER VELDEN VHJ, Dombrink I, Alten J, Cazzaniga G, et al
     Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
     Leukemia. 2024;38:1315-1322.
     PubMed     Abstract available
     
     
     
193. SAYITOGLU EC, Luca BA, Boss AP, Thomas BC, et al
     AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.
     Leukemia. 2024;38:1246-1255.
     PubMed     Abstract available
     
     
     
194. YANG M, Ma Z, Wang C, Agca MC, et al
     Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD.
     Leukemia. 2024;38:1437-1439.
     PubMed    
     
     
     
195. LU W, Lyu H, Xiao X, Bai X, et al
     Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.
     Leukemia. 2024;38:1419-1422.
     PubMed    
     
     
     
196. VAN SPRONSEN MF, Van Gassen S, Duetz C, Westers TM, et al
     Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.
     Leukemia. 2024;38:1365-1377.
     PubMed     Abstract available
     
     
     
197. PERZOLLI A, Koedijk JB, Zwaan CM, Heidenreich O, et al
     Targeting the innate immune system in pediatric and adult AML.
     Leukemia. 2024;38:1191-1201.
     PubMed     Abstract available
     
     
     May 2024
198. ZHU R, Shirley CM, Chu SH, Li L, et al
     Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition.
     Leukemia. 2024 May 29. doi: 10.1038/s41375-024-02292.
     PubMed     Abstract available
     
     
     
199. GALE RP, Hochhaus A
     To Mars and beyond. Space exploration and space medicine in Leukemia.
     Leukemia. 2024 May 22. doi: 10.1038/s41375-024-02286.
     PubMed    
     
     
     
200. RUJKIJYANONT P, Inaba H
     Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.
     Leukemia. 2024 May 18. doi: 10.1038/s41375-024-02277.
     PubMed     Abstract available
     
     
     
201. CORTES JE, Sasaki K, Kim DW, Hughes TP, et al
     Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year follow-up results.
     Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278.
     PubMed     Abstract available
     
     
     
202. MALCIKOVA J, Pavlova S, Baliakas P, Chatzikonstantinou T, et al
     ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.
     Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02267.
     PubMed     Abstract available
     
     
     
203. NEUMANN M, Beder T, Bastian L, Hanzelmann S, et al
     Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
     Leukemia. 2024 May 14. doi: 10.1038/s41375-024-02264.
     PubMed     Abstract available
     
     
     
204. KARAMI A, Skorski T
     DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients.
     Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02269.
     PubMed    
     
     
     
205. AWADA H, Durmaz A, Kewan T, Ullah F, et al
     Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis.
     Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02268.
     PubMed    
     
     
     
206. MORII M, Kubota S, Iimori M, Yokomizo-Nakano T, et al
     TIF1beta activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia.
     Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02276.
     PubMed     Abstract available
     
     
     
207. O'CONNOR KW, Kishimoto K, Kuzma IO, Wagner KP, et al
     The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.
     Leukemia. 2024;38:951-962.
     PubMed     Abstract available
     
     
     
208. SRINIVASAN S, Keerthivasagam S
     Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights.
     Leukemia. 2024;38:1187-1188.
     PubMed    
     
     
     
209. SCHULTZ LM, Jeyakumar N, Kramer AM, Sahaf B, et al
     CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
     Leukemia. 2024;38:963-968.
     PubMed     Abstract available
     
     
     
210. WONG JC, Weinfurtner KM, Westover T, Kim J, et al
     5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
     Leukemia. 2024;38:1182-1186.
     PubMed     Abstract available
     
     
     
211. YI W, Zhang J, Huang Y, Zhan Q, et al
     Ferritin-mediated mitochondrial iron homeostasis is essential for the survival of hematopoietic stem cells and leukemic stem cells.
     Leukemia. 2024;38:1003-1018.
     PubMed     Abstract available
     
     
     April 2024
212. GUO J, Buettner R, Du L, Li Z, et al
     8-Cl-Ado and 8-NH(2)-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia.
     Leukemia. 2024 Apr 20. doi: 10.1038/s41375-024-02222.
     PubMed     Abstract available
     
     
     
213. IYODA S, Yoshida K, Shoji K, Ito N, et al
     KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
     Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244.
     PubMed    
     
     
     
214. NORONHA N, Durette C, Cahuzac M, E Silva B, et al
     Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia.
     Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250.
     PubMed     Abstract available
     
     
     
215. CURIK N, Laznicka A, Polivkova V, Krizkova J, et al
     Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
     Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248.
     PubMed    
     
     
     
216. MATSUI S, Ri C, Bolanos LC, Choi K, et al
     Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.
     Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245.
     PubMed     Abstract available
     
     
     
217. BELL HL, Blair HJ, Jepson Gosling SJ, Galler M, et al
     Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
     Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241.
     PubMed     Abstract available
     
     
     
218. FRUCHTMAN H, Avigan ZM, Waksal JA, Brennan N, et al
     Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
     Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246.
     PubMed     Abstract available
     
     
     
219. BORDINI J, Lenzi C, Frenquelli M, Morabito A, et al
     IkappaBepsilon deficiency accelerates disease development in chronic lymphocytic leukemia.
     Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02236.
     PubMed     Abstract available
     
     
     
220. MCLORNAN DP, Czerw T, Damaj G, Ethell M, et al
     Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
     Leukemia. 2024;38:699-711.
     PubMed     Abstract available
     
     
     
221. LUBKE J, Christen D, Schwaab J, Kaiser A, et al
     Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
     Leukemia. 2024;38:810-821.
     PubMed     Abstract available
     
     
     
222. SHIMONY S, Bewersdorf JP, Shallis RM, Liu Y, et al
     Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
     Leukemia. 2024;38:762-768.
     PubMed     Abstract available
     
     
     
223. SEBERT M, Freiman L, Chaffaut C, Guerci A, et al
     Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
     Leukemia. 2024;38:918-922.
     PubMed    
     
     
     
224. SEVERENS JF, Karakaslar EO, van der Reijden BA, Sanchez-Lopez E, et al
     Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
     Leukemia. 2024;38:751-761.
     PubMed     Abstract available
     
     
     March 2024
225. JASSINSKAJA M, Ghosh S, Watral J, Davoudi M, et al
     A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia.
     Leukemia. 2024 Mar 30. doi: 10.1038/s41375-024-02235.
     PubMed     Abstract available
     
     
     
226. BRIOLI A, Lomaia E, Fabisch C, Sacha T, et al
     Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
     Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204.
     PubMed     Abstract available
     
     
     
227. DE CAMARGO MAGALHAES ES, Hubner SE, Brown BD, Qiu Y, et al
     Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
     Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02208.
     PubMed     Abstract available
     
     
     
228. KANTARJIAN H, Branford S, Breccia M, Cortes J, et al
     Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
     Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229.
     PubMed    
     
     
     
229. BURMEISTER T, Stroh AS, Kehden B, Trautmann H, et al
     Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
     Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209.
     PubMed    
     
     
     
230. FARROKHI A, Atre T, Rever J, Fidanza M, et al
     The Emu-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia.
     Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02221.
     PubMed     Abstract available
     
     
     
231. BONATO A, Chakraborty S, Bomben R, Canarutto G, et al
     NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.
     Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224.
     PubMed     Abstract available
     
     
     
232. ZACKOVA D, Semerad L, Faber E, Klamova H, et al
     Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
     Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215.
     PubMed    
     
     
     
233. SCHWEDE M, Jahn K, Kuipers J, Miles LA, et al
     Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.
     Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211.
     PubMed     Abstract available
     
     
     
234. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
     Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
     Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202.
     PubMed    
     
     
     
235. THOMAS ME 3RD, Qi W, Walsh MP, Ma J, et al
     Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.
     Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02193.
     PubMed     Abstract available
     
     
     
236. PERUSINI MA, Andrews C, Eshetu AG, Gupta V, et al
     Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
     Leukemia. 2024 Mar 2. doi: 10.1038/s41375-024-02201.
     PubMed    
     
     
     
237. MA J, Liu YC, Voss RK, Ma J, et al
     Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
     Leukemia. 2024 Mar 1. doi: 10.1038/s41375-024-02194.
     PubMed     Abstract available
     
     
     
238. CHEN CC, Silberman RE, Ma D, Perry JA, et al
     Inherent genome instability underlies trisomy 21-associated myeloid malignancies.
     Leukemia. 2024;38:521-529.
     PubMed     Abstract available
     
     
     
239. SANZ-ORTEGA L, Andersson A, Carlsten M
     Harnessing upregulated E-selectin while enhancing SDF-1alpha sensing redirects infused NK cells to the AML-perturbed bone marrow.
     Leukemia. 2024;38:579-589.
     PubMed     Abstract available
     
     
     
240. PARRIOTT G, Hegermiller E, Morman RE, Frank C, et al
     Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
     Leukemia. 2024;38:491-501.
     PubMed     Abstract available
     
     
     
241. SPINELLA JF, Chagraoui J, Moison C, Lavallee VP, et al
     DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.
     Leukemia. 2024;38:530-537.
     PubMed     Abstract available
     
     
     
242. BIRDWELL CE, Fiskus W, Kadia TM, Mill CP, et al
     Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
     Leukemia. 2024;38:545-556.
     PubMed     Abstract available
     
     
     February 2024
243. CLAUDIANI S, Chughtai F, Khan A, Hayden C, et al
     Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.
     Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02187.
     PubMed     Abstract available
     
     
     
244. YANG X, Liu J, Liu W, Wu H, et al
     circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation.
     Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02189.
     PubMed     Abstract available
     
     
     
245. FLYGT H, Soderlund S, Richter J, Saussele S, et al
     Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
     Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02184.
     PubMed    
     
     
     
246. MONTALBAN-BRAVO G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, et al
     Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
     Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02190.
     PubMed    
     
     
     
247. JUNK SV, Forster A, Schmidt G, Zimmermann M, et al
     Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia-a case-control study.
     Leukemia. 2024 Feb 27. doi: 10.1038/s41375-024-02173.
     PubMed    
     
     
     
248. CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
     Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
     Leukemia. 2024 Feb 23. doi: 10.1038/s41375-024-02183.
     PubMed     Abstract available
     
     
     
249. OLIVIERI DJ, Othus M, Orvain C, Rodriguez-Arboli E, et al
     Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
     Leukemia. 2024 Feb 22. doi: 10.1038/s41375-024-02172.
     PubMed     Abstract available
     
     
     
250. AVENARIUS MR, Huang Y, Kittai AS, Bhat SA, et al
     Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
     Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02177.
     PubMed    
     
     
     
251. CHATZIKONSTANTINOU T, Agathangelidis A, Chatzidimitriou A, Tresoldi C, et al
     Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia.
     Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02163.
     PubMed    
     
     
     
252. LIN S, Schneider C, Su AH, Alexe G, et al
     The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia.
     Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02178.
     PubMed    
     
     
     
253. DELROCCO NJ, Loh ML, Borowitz MJ, Gupta S, et al
     Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
     Leukemia. 2024 Feb 15. doi: 10.1038/s41375-024-02166.
     PubMed     Abstract available
     
     
     
254. LI Y, Mendoza-Castrejon J, Patel RM, Casey EB, et al
     LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression.
     Leukemia. 2024 Feb 6. doi: 10.1038/s41375-024-02167.
     PubMed    
     
     
     
255. FRANKHOUSER DE, Rockne RC, Uechi L, Zhao D, et al
     State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.
     Leukemia. 2024 Feb 2. doi: 10.1038/s41375-024-02142.
     PubMed     Abstract available
     
     
     
256. KLYUCHNIKOV E, Badbaran A, Massoud R, Freiberger P, et al
     Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.
     Leukemia. 2024;38:386-388.
     PubMed    
     
     
     
257. ELDEEB M, Konturek-Ciesla A, Zhang Q, Kharazi S, et al
     Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis.
     Leukemia. 2024;38:455-459.
     PubMed    
     
     
     
258. GEORGI JA, Stasik S, Kramer M, Meggendorfer M, et al
     Prognostic impact of CEBPA mutational subgroups in adult AML.
     Leukemia. 2024;38:281-290.
     PubMed     Abstract available
     
     
     
259. HEHLMANN R, Lauseker M
     How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.
     Leukemia. 2024;38:465-466.
     PubMed    
     
     
     
260. CHEN J, Gale RP
     Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies.
     Leukemia. 2024;38:463-464.
     PubMed    
     
     
     
261. LEE KH, Lee S, Park YH, Mun YC, et al
     Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis.
     Leukemia. 2024;38:451-454.
     PubMed    
     
     
     
262. MATTANO LA JR, Devidas M, Loh ML, Raetz EA, et al
     Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232.
     Leukemia. 2024;38:258-265.
     PubMed     Abstract available
     
     
     
263. CHEN Y, Wen J, Li Q, Peng D, et al
     RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence and crosstalk with the microenvironment.
     Leukemia. 2024;38:266-280.
     PubMed     Abstract available
     
     
     
264. SUI P, Ge G, Chen S, Bai J, et al
     SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis.
     Leukemia. 2024;38:408-411.
     PubMed    
     
     
     January 2024
265. DAM M, Centanni M, Friberg LE, Centanni D, et al
     Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
     Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02153.
     PubMed     Abstract available
     
     
     
266. JABBOUR E, Apperley J, Cortes J, Rea D, et al
     Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
     Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159.
     PubMed     Abstract available
     
     
     
267. FLYGT H, Soderlund S, Richter J, Saussele S, et al
     Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
     Leukemia. 2024 Jan 26. doi: 10.1038/s41375-024-02145.
     PubMed     Abstract available
     
     
     
268. TAN SH, Tan TK, Yokomori R, Liao M, et al
     Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
     Leukemia. 2024 Jan 25. doi: 10.1038/s41375-023-02125.
     PubMed    
     
     
     
269. TETTERO JM, Heidinga ME, Mocking TR, Fransen G, et al
     Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
     Leukemia. 2024 Jan 25. doi: 10.1038/s41375-024-02158.
     PubMed     Abstract available
     
     
     
270. APPELBAUM JS, Wei AH, Mandrekar SJ, Tiong IS, et al
     Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
     Leukemia. 2024 Jan 23. doi: 10.1038/s41375-024-02143.
     PubMed    
     
     
     
271. KANG H, Hoang DH, Valerio M, Pathak K, et al
     OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia.
     Leukemia. 2024 Jan 17. doi: 10.1038/s41375-024-02146.
     PubMed    
     
     
     
272. TOMA MM, Karami A, Nieborowska-Skorska M, Chirtala KN, et al
     Clonal medicine targeting DNA damage response eradicates leukemia.
     Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02138.
     PubMed    
     
     
     
273. CHEN DW, Fan JM, Schrey JM, Mitchell DV, et al
     Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche.
     Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02136.
     PubMed     Abstract available
     
     
     
274. HANEL G, Schonle A, Neumann AS, Nixdorf D, et al
     Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
     Leukemia. 2024 Jan 11. doi: 10.1038/s41375-023-02127.
     PubMed    
     
     
     
275. VALTIS YK, Flamand Y, Shimony S, Place AE, et al
     Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
     Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02115.
     PubMed     Abstract available
     
     
     
276. SUNG PJ, Selvam M, Riedel SS, Xie HM, et al
     FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
     Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02131.
     PubMed     Abstract available
     
     
     
277. POTLURI S, Kellaway SG, Coleman DJL, Keane P, et al
     Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of FLT3-ITD/NPM1 Acute Myeloid Leukemia but with an altered HOX/MEIS axis.
     Leukemia. 2024 Jan 4. doi: 10.1038/s41375-023-02118.
     PubMed    
     
     
     
278. MORLEY AA
     Quantifying measurable residual disease correctly.
     Leukemia. 2024;38:221-222.
     PubMed    
     
     
     
279. TYAGI A, Jaggupilli A, Ly S, Yuan B, et al
     TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
     Leukemia. 2024;38:82-95.
     PubMed     Abstract available
     
     
     
280. ZHOU YL, Zhao MY, Gale RP, Jiang H, et al
     Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics.
     Leukemia. 2024;38:223-225.
     PubMed    
     
     
     
281. CHEN J
     Response to comment on Have we been qualifying measurable residual disease correctly?
     Leukemia. 2024;38:219-220.
     PubMed    
     
     
     
282. RADIVOYEVITCH T, Gale RP, Kalaycio ME
     What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
     Leukemia. 2024;38:207-209.
     PubMed    
     
     
     
283. GARCIA-MANERO G, Podoltsev NA, Othus M, Pagel JM, et al
     A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
     Leukemia. 2024;38:58-66.
     PubMed     Abstract available
     
     
     
284. YAN M, Liu M, Davis AG, Stoner SA, et al
     Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation.
     Leukemia. 2024;38:31-44.
     PubMed     Abstract available
     
     
     December 2023
285. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
     Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
     Leukemia. 2023 Dec 26. doi: 10.1038/s41375-023-02117.
     PubMed     Abstract available
     
     
     
286. YANADA M, Yamasaki S, Kondo T, Kawata T, et al
     Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission.
     Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02119.
     PubMed     Abstract available
     
     
     
287. MACHOVA POLAKOVA K, Albeer A, Polivkova V, Krutska M, et al
     The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
     Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02109.
     PubMed     Abstract available
     
     
     
288. DE SMITH AJ, Wiemels JL, Mead AJ, Roberts I, et al
     Backtracking to the future: unraveling the origins of childhood leukemia.
     Leukemia. 2023 Dec 20. doi: 10.1038/s41375-023-02111.
     PubMed    
     
     
     
289. FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
     Correction: A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
     Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02112.
     PubMed    
     
     
     
290. MURPHY T, Mason JM, Leber B, Bray MR, et al
     Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
     Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02110.
     PubMed     Abstract available
     
     
     
291. HOFFMEISTER LM, Suttorp J, Walter C, Antoniou E, et al
     Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia.
     Leukemia. 2023 Dec 12. doi: 10.1038/s41375-023-02102.
     PubMed     Abstract available
     
     
     
292. KOVTUN I, von Bonin M, Ibneeva L, Frimmel J, et al
     Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia.
     Leukemia. 2023 Dec 8. doi: 10.1038/s41375-023-02104.
     PubMed    
     
     
     
293. TANNOURY M, Ayoub M, Dehgane L, Nemazanyy I, et al
     ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia.
     Leukemia. 2023 Dec 6. doi: 10.1038/s41375-023-02103.
     PubMed     Abstract available
     
     
     
294. SABA L, Landau KS, Liang H, Fu CL, et al
     Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States.
     Leukemia. 2023 Dec 4. doi: 10.1038/s41375-023-02100.
     PubMed    
     
     
     
295. ANTIC Z, van Bommel A, Riege K, Lentes J, et al
     Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL.
     Leukemia. 2023;37:2522-2525.
     PubMed    
     
     
     
296. SCHIFFER CA
     Glasdigib fails to slay the hedgehog in pivotal AML trials.
     Leukemia. 2023;37:2520-2521.
     PubMed    
     
     
     
297. BOUCHLA A, Papageorgiou SG, Symeonidis A, Sakellari I, et al
     Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
     Leukemia. 2023;37:2517-2519.
     PubMed    
     
     
     
298. XIANG J, Devenport JM, Carter AJ, Staser KW, et al
     An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
     Leukemia. 2023;37:2448-2456.
     PubMed     Abstract available
     
     
     November 2023
299. MILIARA S, Cozzi E, Zhong X, Chan I, et al
     The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia.
     Leukemia. 2023 Nov 30. doi: 10.1038/s41375-023-02098.
     PubMed    
     
     
     
300. PLAYA-ALBINYANA H, Arenas F, Royo R, Giro A, et al
     Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
     Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02095.
     PubMed     Abstract available
     
     
     
301. OZGA M, Nicolet D, Mrozek K, Yilmaz AS, et al
     Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
     Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02068.
     PubMed     Abstract available
     
     
     
302. ROSTI G, Brummendorf TH, Gjertsen BT, Giraldo-Castellano P, et al
     Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
     Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02080.
     PubMed     Abstract available
     
     
     
303. FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
     A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
     Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02096.
     PubMed    
     
     
     
304. LEUNG KT, Cai J, Liu Y, Chan KYY, et al
     Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
     Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02089.
     PubMed     Abstract available
     
     
     
305. ZALIOVA M, Zuna J, Winkowska L, Janotova I, et al
     Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
     Leukemia. 2023 Nov 24. doi: 10.1038/s41375-023-02083.
     PubMed     Abstract available
     
     
     
306. WALTER RB
     Perspective on measurable residual disease testing in acute myeloid leukemia.
     Leukemia. 2023 Nov 16. doi: 10.1038/s41375-023-02084.
     PubMed    
     
     
     
307. WU Y, Zehnle PMA, Rajak J, Koleci N, et al
     BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
     Leukemia. 2023 Nov 9. doi: 10.1038/s41375-023-02079.
     PubMed     Abstract available
     
     
     
308. ALSHAMLEH I, Kurrle N, Makowka P, Bhayadia R, et al
     PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.
     Leukemia. 2023 Nov 7. doi: 10.1038/s41375-023-02041.
     PubMed     Abstract available
     
     
     
309. TOMIZAWA D, Matsubayashi J, Iwamoto S, Hiramatsu H, et al
     High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
     Leukemia. 2023 Nov 6. doi: 10.1038/s41375-023-02075.
     PubMed    
     
     
     
310. HUUHTANEN J, Adnan-Awad S, Theodoropoulos J, Forsten S, et al
     Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
     Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02074.
     PubMed     Abstract available
     
     
     
311. WEISCHENDORFF S, Rathe M, Petersen MJ, Weimann A, et al
     Markers of intestinal mucositis to predict blood stream infections at the onset of fever during treatment for childhood acute leukemia.
     Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02077.
     PubMed     Abstract available
     
     
     
312. FALINI B, Gjertsen BT, Andresen V
     The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?
     Leukemia. 2023;37:2173-2175.
     PubMed    
     
     
     
313. LAUSEKER M, Hehlmann R, Hochhaus A, Saussele S, et al
     Survival with chronic myeloid leukaemia after failing milestones.
     Leukemia. 2023;37:2231-2236.
     PubMed     Abstract available
     
     
     
314. DU W, Xia Z, Luo Z, Chen Y, et al
     A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML.
     Leukemia. 2023;37:2286-2291.
     PubMed    
     
     
     
315. BUROCZIOVA M, Danek P, Oravetzova A, Chalupova Z, et al
     Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.
     Leukemia. 2023;37:2209-2220.
     PubMed     Abstract available
     
     
     
316. FENG Y, Qi S, Liu X, Zhang L, et al
     Have we been qualifying measurable residual disease correctly?
     Leukemia. 2023;37:2168-2172.
     PubMed    
     
     
     
317. LI S, Wang X, Liu L, Liu J, et al
     CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
     Leukemia. 2023;37:2176-2186.
     PubMed     Abstract available
     
     
     October 2023
318. CERELLA C, Gajulapalli SR, Lorant A, Gerard D, et al
     ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.
     Leukemia. 2023 Oct 30. doi: 10.1038/s41375-023-02076.
     PubMed     Abstract available
     
     
     
319. BISCHOF L, Ussmann J, Grimm J, Bill M, et al
     Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
     Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02072.
     PubMed    
     
     
     
320. V STACKELBERG A, Jaschke K, Jousseaume E, Templin C, et al
     Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
     Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02042.
     PubMed     Abstract available
     
     
     
321. WU A, Yen R, Grasedieck S, Lin H, et al
     Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
     Leukemia. 2023 Oct 17. doi: 10.1038/s41375-023-02062.
     PubMed     Abstract available
     
     
     
322. JOHANSSON KB, Zimmerman MS, Dmytrenko IV, Gao F, et al
     Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
     Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02057.
     PubMed     Abstract available
     
     
     
323. DEL GIUDICE I, Foa R
     Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?
     Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02066.
     PubMed    
     
     
     
324. ECKARDT JN, Stasik S, Rollig C, Petzold A, et al
     Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
     Leukemia. 2023 Oct 13. doi: 10.1038/s41375-023-02061.
     PubMed     Abstract available
     
     
     
325. OTTONE T, Silvestrini G, Piazza R, Travaglini S, et al
     Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways.
     Leukemia. 2023 Oct 6. doi: 10.1038/s41375-023-02054.
     PubMed     Abstract available
     
     
     
326. KANTARJIAN HM
     What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia.
     Leukemia. 2023 Oct 5. doi: 10.1038/s41375-023-02053.
     PubMed    
     
     
     
327. TULKENS D, Boelens M, Naert T, Carron M, et al
     Mutations in the histone methyltransferase Ezh2 drive context-dependent leukemia in Xenopus tropicalis.
     Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02052.
     PubMed     Abstract available
     
     
     
328. CROSS NCP, Ernst T, Branford S, Cayuela JM, et al
     European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
     Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02048.
     PubMed     Abstract available
     
     
     
329. JAHN E, Saadati M, Fenaux P, Gobbi M, et al
     Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
     Leukemia. 2023 Oct 3. doi: 10.1038/s41375-023-02017.
     PubMed    
     
     
     
330. HUBER S, Baer C, Hutter S, Dicker F, et al
     Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.
     Leukemia. 2023;37:2138-2141.
     PubMed    
     
     
     
331. OTHMAN J, Potter N, Mokretar K, Taussig D, et al
     FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
     Leukemia. 2023;37:2066-2072.
     PubMed     Abstract available
     
     
     
332. FISHER JG, Doyle ADP, Graham LV, Sonar S, et al
     XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
     Leukemia. 2023;37:2036-2049.
     PubMed     Abstract available
     
     
     
333. CASERTA C, Nucera S, Barcella M, Fazio G, et al
     miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
     Leukemia. 2023;37:1994-2005.
     PubMed     Abstract available
     
     
     
334. TIAN Z, Shi C, Yang G, Allen JK, et al
     Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
     Leukemia. 2023;37:2006-2016.
     PubMed     Abstract available
     
     
     
335. GURULE NJ, Malcolm KC, Harris C, Knapp JR, et al
     Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
     Leukemia. 2023;37:2115-2124.
     PubMed     Abstract available
     
     
     September 2023
336. MALIK N, Hay J, Almuhanna HNB, Dunn KM, et al
     mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia.
     Leukemia. 2023 Sep 29. doi: 10.1038/s41375-023-02043.
     PubMed     Abstract available
     
     
     
337. JONDREVILLE L, Dehgane L, Doualle C, Smagghe L, et al
     del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
     Leukemia. 2023 Sep 26. doi: 10.1038/s41375-023-02035.
     PubMed     Abstract available
     
     
     
338. FECHINA L, Popov A, Tsaur G, Henze G, et al
     Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
     Leukemia. 2023 Sep 23. doi: 10.1038/s41375-023-02034.
     PubMed    
     
     
     
339. KUBASCH AS, Peterlin P, Cluzeau T, Gotze KS, et al
     Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
     Leukemia. 2023 Sep 21. doi: 10.1038/s41375-023-02029.
     PubMed    
     
     
     
340. DOBISH KK, Wittorf KJ, Swenson SA, Bean DC, et al
     FBXO21 mediated degradation of p85alpha regulates proliferation and survival of acute myeloid leukemia.
     Leukemia. 2023 Sep 9. doi: 10.1038/s41375-023-02020.
     PubMed     Abstract available
     
     
     
341. ECKARDT JN, Bill M, Rausch C, Metzeler K, et al
     Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification.
     Leukemia. 2023 Sep 7. doi: 10.1038/s41375-023-02016.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.